Lumicell Appoints Felix Geissler, M.D., Ph.D. as Chief Medical Officer

Burgeoning Demand for MRI-guided Radiation Therapy Systems Market to Fuel Market Growth Thorough the COVID-19 Crisis Period

The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by Fact.MR.

COVID-19 to Substantially Increase the Demand for 3D Printing Medical Devices Market from Key End-use Industry Sectors Unveils Fact.MR

The global 3D printing medical devices market is expected to exceed US$ 1,700 Mn in revenues by 2022-end, according to a recent research by Fact.MR.

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Felix Geissler
Felix Geissler, MD, Chief Medical Officer at Lumicell, Inc.

Lumicell, (field of image-guided cancer surgery), today announced the appointment of Felix Geissler, M.D., Ph.D. as Chief Medical Officer. As a central member of Lumicell’s senior executive team, he will drive the clinical direction of the company and will work closely with the R&D and marketing teams to develop the overall business strategy.

Dr. Geissler previously held various roles within Sanofi Genzyme. Most recently, he was the medical head for the oncology department at Sanofi Genzyme and prior to that he was stationed in Tokyo as the CMO for the Asia-Pacific Region. Prior to Sanofi, Dr. Geissler worked for Novartis and BMS in various capacities. Before joining the pharmaceutical industry, Felix was a transplant surgeon at the UW Hospital in Madison, WI. He received his surgical training at the University of Leipzig, Germany where his focus was hepatobiliary and pancreatic surgery. During this time, he established a molecular research laboratory to identify circulating tumor cells. Felix received his M.D. from the Technical University of Munich and his Ph.D. from the University of Tubingen. During his academic tenure, he has published over 30 articles and several book chapters.

W. David Lee, CEO of Lumicell said, “Felix’s surgical expertise tied with his experience as a senior medical leader at Sanofi Genzyme, will be a huge asset to Lumicell and our expanding pipeline of surgical technologies.”  He concluded, “I am very pleased to welcome him to our expanding team.”

Every year more than 60,000 women undergoing lumpectomy must endure re-excision due to positive margins discovered on final histopathology examination. Second surgeries increase discomfort, add emotional and cosmetic expenses to the patient, and may cost the healthcare system close to $1 billion annually. Lumicell is working to address this unmet medical need.



Subscribe to Medical Device News Magazine here.

Related Articles